Back
Anterix, Inc. 10K Form
Sell
44
ATEX
Anterix, Inc.
Last Price:
$20.24
Seasonality Move:
6.78%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2021-02-08 | 10Q | ATEX/Anterix, Inc. Quarterly |
| 2020-11-16 | 10Q | ATEX/Anterix, Inc. Quarterly |
| 2020-08-06 | 10Q | ATEX/Anterix, Inc. Quarterly |
| 2020-05-28 | 10K | ATEX/Anterix, Inc. Annual |
| 2020-02-04 | 10Q | ATEX/Anterix, Inc. Quarterly |
| 2019-11-06 | 10Q | ATEX/Anterix, Inc. Quarterly |
Receive ATEX News And Ratings
See the #1 stock for the next 7 days that we like better than ATEX
ATEX Financial Statistics
Sales & Book Value
| Annual Sales: | $6M |
|---|---|
| Cash Flow: | $-11.8M |
| Price / Cash Flow: | 40.13 |
| Annual Sales: | $12.85 |
| Price / Book: | 1.58 |
Profitability
| EPS (TTM): | 5.11090 |
|---|---|
| Net Income (TTM): | $95.6M |
| Gross Margin: | $5.5M |
| Return on Equity: | 55.25% |
| Return on Assets: | 27% |
Anterix, Inc. Earnings Forecast
Key Anterix, Inc. Financial Ratios
-
The Gross Profit Margin over the past 13 years for ATEX is 90.83%.
-
The Selling, General & Administrative Expenses for ATEX have been equal to 808.84% of Gross Profit Margin.
-
The Research & Development expenses have been 95.09% of Revenue.
-
The Net Earning history of ATEX is -188.56% of Total Revenues.
-
Per Share Earnings over the last 13 years have been positive in 6 years.
Anterix, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Diversified Telecommunication Services |
| Sector: | Communication Services |
| Current Symbol: | ATEX |
| CUSIP: | 03676C |
| Website: | anterix.com |
Debt
| Debt-to-Equity Ratio: | 0.02 |
|---|---|
| Current Ratio: | 1.7 |
| Quick Ratio: | 1.61 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 25.01 |
ATEX Technical Analysis vs Fundamental Analysis
Sell
44
Anterix, Inc. (ATEX)
is a Sell
Is Anterix, Inc. a Buy or a Sell?
-
Anterix, Inc. stock is rated a SellThe current Anterix, Inc. [ATEX] share price is $20.30. The Score for ATEX is 44, which is 12% below its historic median score of 50, and infers higher risk than normal.